Report
← Signal Board

Anika Therapeutics financial statements

아니카 테라퓨틱스NASDAQ:ANIK · Nasdaq · Healthcare · sector #20
$19.23-1.54%
2026-10-08 close · prelim

Anika Therapeutics's published financial data is dated 2026-10-04. 2024 revenue was $120M. 2024 operating profit was −$5M.

Reported results

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 7.22
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
7.22
Beneish M-Score
-4.25

No statistical flag

Sloan accrual
-30.48%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

5/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score5/9

Profitability

  • Positive ROANot passed
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업외손익 급변 (영업이익 대비 1103% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-4.3%
Interest coverage
-0.1x
Return on equity (ROE)
-36.6%

Operating margin −5pp

Operating loss
Interest coverageBase -0.1x adverse case -0.2x
Return on equity (ROE)Base -36.6% adverse case -40.5%

Revenue −15%

Interest coverage risk
Interest coverageBase -0.1x adverse case -0.1x
Return on equity (ROE)Base -36.6% adverse case -36.1%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -0.1x adverse case -0.1x
Return on equity (ROE)Base -36.6% adverse case -37.2%

Interest coverage limit

Already below the limit by 47pp

Interest coverage limit at an operating margin of 42.8%

Interest expense coverage threshold

Anika Therapeutics notifications

Quantus Signal · live data · not investment advice · Privacy Policy